4.7 Article

Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 107, Issue 10, Pages E4004-E4014

Publisher

ENDOCRINE SOC
DOI: 10.1210/clinem/dgac469

Keywords

gender dysphoria; pediatric; cardiometabolic; cholesterol; body mass index; hormone therapy

Funding

  1. National Institutes of Health/National Institute of Child Health and Human Development (National Institutes of Health (NIH)/National Institute of Child Health and Human Development (NICHD)) [K23HD092588, R03HD102773]
  2. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [K23HL151868]
  3. Doris Duke Foundation
  4. National Institute of Diabetes and Digestive and Kidney Diseases [T325T32DK063687]
  5. Pediatric Endocrine Society
  6. Society for Adolescent Health and Medicine (A.V.)

Ask authors/readers for more resources

This study using a large database found that transgender and gender-diverse youth have an increased risk of overweight/obesity compared to matched controls. Screening and tailored weight management for TGDY are necessary.
Context Studies on cardiometabolic health in transgender and gender-diverse youth (TGDY) are limited to small cohorts. Objective This work aimed to determine the odds of cardiometabolic-related diagnoses in TGDY compared to matched controls in a cross-sectional analysis, using a large, multisite database (PEDSnet). Methods Electronic health record data (2009-2019) were used to determine odds of cardiometabolic-related outcomes based on diagnosis, anthropometric, and laboratory data using logistic regression among TGDY youth vs controls. The association of gender-affirming hormone therapy (GAHT) with these outcomes was examined separately among TGDY. TGDY (n = 4172) were extracted from 6 PEDSnet sites and propensity-score matched on 8 variables to controls (n = 16 648). Main outcomes measures included odds of having cardiometabolic-related diagnoses among TGDY compared to matched controls, and among TGDY prescribed GAHT compared to those not prescribed GAHT. Results In adjusted analyses, TGDY had higher odds of overweight/obesity (1.2; 95% CI, 1.1-1.3) than controls. TGDY with a testosterone prescription alone or in combination with a gonadotropin-releasing hormone agonist (GnRHa) had higher odds of dyslipidemia (1.7; 95% CI, 1.3-2.3 and 3.7; 95% CI, 2.1-6.7, respectively) and liver dysfunction (1.5; 95% CI, 1.1-1.9 and 2.5; 95% CI, 1.4-4.3) than TGDY not prescribed GAHT. TGDY with a testosterone prescription alone had higher odds of overweight/obesity (1.8; 95% CI, 1.5-2.1) and hypertension (1.6 95% CI, 1.2-2.2) than those not prescribed testosterone. Estradiol and GnRHa alone were not associated with greater odds of cardiometabolic-related diagnoses. Conclusion TGDY have increased odds of overweight/obesity compared to matched controls. Screening and tailored weight management, sensitive to the needs of TGDY, are needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available